NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
January 21, 2025 16:20 ET
|
NurExone Biologic Inc
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director
Olympia Pharmaceuticals Expands into Alabama with New Licensing, Bringing GLP-1s and More to Healthcare Providers
January 21, 2025 09:00 ET
|
Olympia Pharmaceuticals
ORLANDO, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals, a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility, is proud to announce its expansion into...
Radical Catheter Technologies’ 8F Neurovascular Catheter Receives US FDA 510(k) Clearance, Second for the Best-in-Class Ribbon Technology Platform
January 15, 2025 09:00 ET
|
Radical Catheter Technologies
CAMPBELL, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Radical™ Catheter Technologies, a pioneering medical device company focused on advancing the next generation of endovascular access and delivery,...
Washington Post Story Featuring 22nd Century VLN Products Highlights Proposed FDA Reduced Nicotine Content Policy Could Initially Benefit An Estimated 13 Million Smokers
January 14, 2025 09:25 ET
|
22nd Century Group, Inc.
VLN Reduced Nicotine Content Cigarettes from 22nd Century Is the Only Authorized Combustible Solution to Support the FDA’s War on Smoking MOCKSVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- 22nd...
FDA Approves Feasibility Study with SeaStar Medical’s Selective Cytopheretic Device in Adults with Cardiorenal Syndrome
January 13, 2025 08:30 ET
|
SeaStar Medical Holding Corporation
Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing...
22nd Century Stands Ready to Support the Adoption of FDA Proposed Tobacco Product Standard to Mandate Reduced Nicotine Content in Cigarettes with its VLN Cigarettes
January 13, 2025 07:30 ET
|
22nd Century Group, Inc.
FDA Reduced Nicotine Content Proposal Indicated to Have Completed OMB Review as of January 3, 2025 FDA Spokesperson Indicates Policy Could Be Among Most Impactful Population-Level Actions in the...
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
January 13, 2025 07:00 ET
|
CytoSorbents
CytoSorbents Strengthens Balance Sheet by $11.25M in Unrestricted Cash through Oversubscribed Shareholder Rights Offering and Satisfied Debt Covenant
Theratechnologies fait le point sur l’approvisionnement d’EGRIFTA SV(MD)
January 09, 2025 17:05 ET
|
Theratechnologies
MONTRÉAL, 09 janv. 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies Provides Update on EGRIFTA SV® Supply
January 09, 2025 17:05 ET
|
Theratechnologies
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
NurExone Biologic Secures Master Cell Bank
January 08, 2025 16:12 ET
|
NurExone Biologic Inc
NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production